U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07542483) titled 'A Study of Lebrikizumab in Adults With Nummular Eczema' on April 15.
Brief Summary: The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Nummular Eczema
Intervention:
DRUG: Lebrikizumab
Lebrikizumab SC injection.
OTHER: Placebo
Matching placebo SC injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Almirall, S.A.
Disclaimer: Cura...